Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALPL | P05186 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14825147 | 0.87 | P2RX7 (0.62) | LMNATP53ALOX15TSHRP2RX7 | |
| SCHEMBL19657272 | 0.86 | KMT2A (0.62) | LMNATP53ALOX15TSHRP2RX7 | |
| SCHEMBL24508969 | 0.85 | P2RX7 (0.60) | LMNATP53ALOX15TSHRP2RX7 | |
| SCHEMBL1448439 | 0.84 | LMNA (0.60) | LMNATP53ALOX15TSHRP2RX7 | |
| SCHEMBL30309430 | 0.84 | LMNA (0.60) | LMNATP53ALOX15TSHRP2RX7 | |
| SCHEMBL2522286 | 0.84 | LMNA (0.60) | LMNATP53ALOX15TSHRP2RX7 | |
| SCHEMBL30031976 | 0.84 | LMNA (0.60) | LMNATP53ALOX15TSHRP2RX7 | |
| SCHEMBL1155983 | 0.84 | TP53 (0.68) | LMNATP53ALOX15TSHRP2RX7 | |
| SCHEMBL29944105 | 0.83 | MEN1 (0.62) | LMNATP53ALOX15TSHRP2RX7 | |
| SCHEMBL11488934 | 0.83 | MEN1 (0.62) | LMNATP53ALOX15TSHRP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028489-A1 | Pyrimidine Derivatives and Their Use for Treating Bone-Related Disorders | ANDERSSON LARS | 2011-02-03 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-7449485-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080214560-A1 | Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| EP-1945628-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| EP-1942897-A1 | USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE | AstraZeneca AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080146572-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2007040440-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040436-A1 | USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146572-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | BAX, BCL2, BAD | LMNA 277/4885TP53 77/4885ALOX15 1616/4885 |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | LMNA 141/4885TP53 30/4885ALOX15 2494/4885 |
| US-20080214560-A1 | Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | TYMS, TYMP, ADORA1 | LMNA 3904/4885TP53 299/4885ALOX15 3229/4885 |
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | DPYD, TYMS, TYMP | LMNA 2077/4885TP53 76/4885ALOX15 3631/4885 |
| US-20110028489-A1 | Pyrimidine Derivatives and Their Use for Treating Bone-Related Disorders | TYMP, DPYD, HPRT1 | LMNA 2446/4885TP53 366/4885ALOX15 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.